
BioCryst Pharmaceuticals Investor Relations Material
Latest events

Q4 2024
BioCryst Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from BioCryst Pharmaceuticals Inc
Access all reports
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company offers peramivir, an intravenous neuraminidase inhibitor, which completed Phase III clinical trial for the treatment of acute uncomplicated influenza in hospitalized adult and pediatric patients in Japan; BCX4161, an oral purine nucleoside phosphorylase (PNP) inhibitor for the treatment of hereditary angioedema; galidesivir, a broad spectrum viral RNA polymerase inhibitor that is under pre-clinical development against various high priority viruses associated with biodefense threat; and BCX9250 that is under pre-clinical development for the treatment of gout.
Key slides for BioCryst Pharmaceuticals Inc


Q1 2024
BioCryst Pharmaceuticals Inc


Q2 2024
BioCryst Pharmaceuticals Inc
Latest articles
)
Moncler: From the Mountains to the Runway
The story of Moncler, all the way from its beginnings in the Alps to its journey to some of the most prestigious runways in the world.
16 Apr 2025
)
eToro: Innovation, Growth, and IPO Plans
eToro was founded in 2007 and has grown into a global trading platform with over 40 million users and an extensive offering across several asset classes.
10 Apr 2025
)
Yum! Brands: The Company Behind Pizza Hut, KFC, and Taco Bell
Yum! Brands started at PepsiCo in the 1970s and is home to some of the most well-known brands in the world, such as Pizza Hut, KFC, and Taco Bell.
9 Apr 2025
Ticker symbol
BCRX
Country
🇺🇸 United States